IP Library Granted Patent US 9,937,129
Granted Patent B2
US 9,937,129 · App. 15/004,790 · Granted Apr 10, 2018

Materials and methods for delivering compositions to selected tissues

Inventors: William R. Freeman (Del Mar, CA); Michael J. Sailor (La Jolla, CA); Lingyun Cheng (San Diego, CA)
Assignee: The Regents of the University of California
A61K9/143A61K9/0019A61K9/0051A61K9/14A61K9/5115A61K9/7007A61K31/573A61K31/7088A61K38/482A61K39/395A61K39/44C25F3/12A61K2039/505A61K2039/54C12Y304/21073
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,129
App. No.
15/004,790
Granted
Apr 10, 2018
Kind
B2
Abstract

This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.

Claims (19)

1. A method of preparing a composition for controlled drug delivery comprising:

providing a porous silicon film;

heating the porous silicon film in an oxidizing environment at a temperature above 600° C.,

preparing particles from the oxidized porous silicon film; and

treating the oxidized porous silicon particles with a drug or biologically active material.

2. The method of claim 1 , wherein the particles have a size of between about 0.1 μm and about 100 μm.

3. The method of claim 1 , wherein the porous silicon film comprises pores with a free volume of from 50% to 80%.

4. The method of claim 1 , wherein the drug or biologically active material is a protein.

5. The method of claim 4 , wherein the drug or biologically active material is bevacizumab, ranibizumab, or pegaptanib.

6. The method of claim 1 , wherein the drug of biologically active material is selected from the group consisting of angiostatic steroids, metalloproteinase inhibitors, VEGF binding drugs, PEDF, an 8-mer peptide fragment of urokinase (uPA), and dexamethasone.

7. The method of claim 1 , wherein the drug or biologically active material targets a disease or disorder of the eye.

8. The method of claim 7 , wherein the disease or disorder of the eye is selected from the group consisting of: age-related macular degeneration (AMD), choroidal neovascularization (CNV), uveitis, diabetic retinopathy, retinovasclar disease, retinal detachment (PVR), and glaucoma.

9. The method of claim 1 , wherein the porous silicon film comprises a layered nanostructure.

10. The method of claim 1 , comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 700° C.

11. The method of claim 1 , comprising the step of heating the porous silicon film in an oxidizing environment at a temperature above 800° C.

12. The method of claim 1 , wherein particles are prepared from the oxidized porous silicon film after the porous silicon film is heated in an oxidizing environment at a temperature above 600° C.

13. The method of claim 1 , wherein the porous silicon film comprises pores selectively dimensioned to obtain a desired reflective wavelength.

14. The method of claim 1 , further comprising the step of capping the porous silicon film with a polymeric material.

15. The method of claim 1 , wherein the porous silicon film comprises pores configured to enhance binding efficacy of the drug or biologically active material.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2018
From: FREEMAN, WILLIAM R.; SAILOR, MICHAEL J.; CHENG, LINGYUN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 044578/0478 →
CONFIRMATORY LICENSE Recorded Jul 11, 2016
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039299/0624 →
Continuity (4)
Continuation 13887045 · May 3, 2013
Division 12668349
Provisional Application 60948816 · Jul 10, 2007
Related Publication 20160338960A1 · Nov 24, 2016